By Colin Kellaher

 

AbbVie Inc. on Tuesday reported positive top-line results from a pair of Phase 3 studies of its psoriasis treatment Skyrizi in adults with active psoriatic arthritis.

The North Chicago, Ill., biopharmaceutical company said significantly more patients treated with Skyrizi achieved the primary response endpoint in joint symptoms at week 24 versus placebo.

AbbVie also said the results of ranked secondary endpoints showed significant improvements in skin clearance, physical function and minimal disease activity at week 24.

Skyrizi, which received U.S. and European approval in 2019 for adults with moderate to severe plaque psoriasis, is part of a collaboration between AbbVie and Boehringer Ingelheim, a family-owned pharmaceutical company based in Ingelheim, Germany. AbbVie leads the global development and commercialization of the drug, which is also in Phase 3 trials for psoriasis and Crohn's disease.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

January 05, 2021 09:59 ET (14:59 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.